Interleukin-18, from neuroinflammation to Alzheimer's disease.

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide directly related to the progressive increase in overweight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response a...

journal_title：Current pharmaceutical design

authors： Tejada S,Capó X,Mascaró CM,Monserrat-Mesquida M,Quetglas-Llabrés MM,Pons A,Tur JA,Sureda A

更新日期：2020-04-17 00:00:00

abstract：:The use of the carbohydrate glucose as an energetic source is essential for an adequate function of the human body. The complex regulation of this molecule involves the coordinated action of various organs such as pancreas, liver and brain. Any disruption of this physiological balance may result in a dangerous comprom...

journal_title：Current pharmaceutical design

authors： González-Reyes RE,Aliev G,Ávila-Rodrigues M,Barreto GE

更新日期：2016-01-01 00:00:00

abstract：:Apoptosis is a regulated process leading to cell death, which is implicated both in normal development and in various pathologies including heart failure, stroke and neurodegenerative diseases. Caspase-3, a key enzyme of the apoptotic pathway, is considered as a major target for the treatment of abnormal cell death. M...

journal_title：Current pharmaceutical design

authors： Seaborn T,Masmoudi-Kouli O,Fournier A,Vaudry H,Vaudry D

更新日期：2011-01-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, local anti- VEGF therapy was developed and established to treat proliferative diabetic retinopathy, age-related macular...

journal_title：Current pharmaceutical design

authors： van der Giet M,Henkel C,Schuchardt M,Tolle M

更新日期：2015-01-01 00:00:00

abstract：:In the last two decades quantitative electroencephalogram (EEG) analysis has been widely used to investigate the neurophysiological characteristics of insomnia. These studies provided evidence in support of the hypothesis that primary insomnia is associated with hyperarousal of central nervous system and altered sleep...

journal_title：Current pharmaceutical design

authors： Marzano C,Ferrara M,Sforza E,De Gennaro L

更新日期：2008-01-01 00:00:00

abstract：:Cancer disease is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and around 8 million cancer-related deaths yearly. Estimates expect to increase these figures over the next few years. Therefore, it is very important to develop more effective and targeted therapi...

journal_title：Current pharmaceutical design

authors： Caro C,Pozo D

更新日期：2015-01-01 00:00:00

abstract：:Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerat...

journal_title：Current pharmaceutical design

authors： Unoki H,Yamagishi S

更新日期：2008-01-01 00:00:00

abstract：:In recent years, new strategies in cancer therapy have been developed targeting key signaling molecules in the receptor tyrosine kinase signal transduction pathway. In contrast, most therapeutical concepts to manipulate G protein-coupled receptors (GPCR)-mediated disorders are still limited to the use of receptor-spec...

journal_title：Current pharmaceutical design

authors： Liebmann C

更新日期：2004-01-01 00:00:00

abstract：:Vasopressin (AVP) secretion and release are regulated by a number of central nervous system sites that receive peripheral signals from the osmoreceptors and baroreceptors. Aim of this paper is to review anatomical pathways and neurotransmitters involved as well as drugs affecting AVP secretion. ...

journal_title：Current pharmaceutical design

authors： Iovino M,Guastamacchia E,Giagulli VA,Licchelli B,Triggiani V

更新日期：2012-01-01 00:00:00

abstract：:Diabetic retinopathy remains the most common microvascular complication suffered by diabetic patients and is the leading cause of registerable blindness in the working population of developed countries. The clinicopathological lesions of diabetic retinopathy have been well characterised and although a multitude of pat...

journal_title：Current pharmaceutical design

authors： Stitt AW,Frizzell N,Thorpe SR

更新日期：2004-01-01 00:00:00

abstract：:Increased plasma levels of both leptin and C reactive protein (CRP) have been reported in a number of conditions, including obesity, and have been linked to cardiovascular pathophysiological processes and increased cardiovascular risk; interestingly these two biomarkers appear to be able to reciprocally regulate their...

journal_title：Current pharmaceutical design

authors： Hribal ML,Fiorentino TV,Sesti G

更新日期：2014-01-01 00:00:00

abstract：:Clopidogrel, in combination wih aspirin, is currently the drug of choice to prevent thrombosis after coronary stent implantation. Currently, clopidogrel is administered to the vast majority of patients without any assessment of platelet inhibition. Response variability and resistance, however, definitely occur to clop...

journal_title：Current pharmaceutical design

authors： Gurbel PA,Lau WC,Bliden KP,Tantry US

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Cancer and its treatment therapies, such as chemotherapy and radiotherapy, have negative effects on taste and smell functions. It is easy to explain smell and taste dysfunctions when a cancer involves the peripheric end organs or neurologic pathways of smell and taste. However, it is difficult to understand ...

journal_title：Current pharmaceutical design

authors： Altundag A,Cayonu M

更新日期：2016-01-01 00:00:00

abstract：:High molecular weight kininogen (HK) is a plasma protein that is cleaved by plasma kallikrein in the clinical settings of sepsis and chronic inflammatory diseases such as rheumatoid arthritis and Crohn's disease. This proteolytic event results in a nonapeptide, bradykinin (BK), and a kinin-free derivative of HK, namel...

journal_title：Current pharmaceutical design

authors： Colman RW

更新日期：2006-01-01 00:00:00

abstract：:We have gained considerable insight and understanding about the etiology, embryogenesis of the myocardium, genetic background, diagnosis and outcome of left ventricular non-compaction (LVNC) over the last 2 decades. LVNC has a distinct morphological appearance with a thickened, two-layered myocardium consisting of an ...

journal_title：Current pharmaceutical design

authors： Ganame J

更新日期：2015-01-01 00:00:00

abstract：:In patients with acute coronary syndromes (ACS), hypertension is common. The type of ACS and severity of hypertension would determine the treatment algorithm. In ST elevation myocardial infarction (MI), time to reperfusion is essential whereas in malignant hypertension the reduction of blood pressure to prevent end or...

journal_title：Current pharmaceutical design

authors： Kühl M,Lip GY,Varma C

更新日期：2007-01-01 00:00:00

abstract：:Inhibition of the renin-angiotensin system (RAS) has been shown to have beneficial effects in cardiovascular disease prognosis and therapy.Discovery of (pro)renin receptor [(P)RR] revealed that (P)RR upon binding to both renin or prorenin in their proenzyme inactive form made them enzymatically active, thus aiding the...

journal_title：Current pharmaceutical design

authors： Ando T,Ichihara A

更新日期：2014-01-01 00:00:00

abstract：:The final aim/target of Pharmaceutical Sciences is to design successful dosage forms for effective therapy, considering individual patient needs and compliance. Development of new drug entities, particularly using peptides and proteins, is growing in importance and attracting increased interest, as they are specifical...

journal_title：Current pharmaceutical design

authors： Degim IT,Celebi N

更新日期：2007-01-01 00:00:00

abstract：:Fibrates are widely prescribed lipid-lowering drug in the treatment of dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative activated receptor (PPAR) alpha activation, are a moderate reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, a marked reduction in ...

journal_title：Current pharmaceutical design

authors： Ansquer JC,Foucher C,Aubonnet P,Le Malicot K

更新日期：2009-01-01 00:00:00

abstract：:α-Synuclein aggregation is centrally implicated in Parkinson's disease (PD). It involves multi-step nucleated polymerization process via the formation of dimers, soluble toxic oligomers and insoluble fibrils. In the present study, we synthesized a novel compound viz., Curcumin-glucoside (Curc-gluc), a modified form of...

journal_title：Current pharmaceutical design

authors： Gadad BS,Subramanya PK,Pullabhatla S,Shantharam IS,Rao KS

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Bio-soft material, a class of derivatives of the natural or synthetic material, is getting more and more prevalent in biomedical researches and applications due to the advantages such as in-vivo biodegradation, good water solubility and designable targeting ability. With the presence of bio-sof...

journal_title：Current pharmaceutical design

authors： Chen N,Su T,Cheng Z,An F

更新日期：2018-01-01 00:00:00

abstract：:The brain is a complex, regulated organ with a highly controlled access mechanism: The Blood-Brain Barrier (BBB). The selectivity of this barrier is a double-edged sword, being both its greatest strength and weakness. This weakness is evident when trying to target therapeutics against diseases within the brain. Diseas...

journal_title：Current pharmaceutical design

authors： McCully M,Sanchez-Navarro M,Teixido M,Giralt E

更新日期：2018-01-01 00:00:00

abstract：:Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are val...

journal_title：Current pharmaceutical design

authors： Andrews KT,Tran TN,Fairlie DP

更新日期：2012-01-01 00:00:00

abstract：:Drug-drug interactions may occur when to combine two or more drugs and may cause some adverse events such as Cardiotoxicity, Central neurotoxicity, Hepatotoxicity, etc. Although a large number of researchers who are proficient in pharmacokinetics and pharmacodynamics have been engaged in drug assays and trying to find...

journal_title：Current pharmaceutical design

authors： Huang W,Li C,Ju Y,Gao Y

更新日期：2021-01-27 00:00:00

abstract：:Patients with diabetes mellitus (DM) type 2 have a high prevalence of coronary artery disease (CAD), as diabetes is implicated in the formation of atherosclerotic plaque. Hyperglycemia, elevated free fatty acid, increased amount of circulating end-glucosylated serum products and insulin resistance are the main mechani...

journal_title：Current pharmaceutical design

authors： Tousoulis D,Kampoli AM,Papageorgiou N,Papaoikonomou S,Antoniades C,Stefanadis C

更新日期：2009-01-01 00:00:00

abstract：:The clinically most relevant medications for lipid management are the statins, which constitute in the majority of the cases the basis of any lipid-modulating therapy. However, other agents are often needed to either reduce low-density cholesterol to target levels and/or to treat residual serum lipoprotein abnormaliti...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Berthold HK

更新日期：2013-01-01 00:00:00

abstract：:Hyperferritinemia is observed in one-third of patients with non-alcoholic fatty liver disease (NAFLD) and Metabolic Syndrome (MetS). The condition characterized by increased body iron stores associated with components of MetS has been defined as Dysmetabolic Iron Overload Syndrome (DIOS). DIOS represents the most freq...

journal_title：Current pharmaceutical design

authors： Rametta R,Fracanzani AL,Fargion S,Dongiovanni P

更新日期：2020-01-01 00:00:00

abstract：:The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer dr...

journal_title：Current pharmaceutical design

authors： Zhan C,Lu W

更新日期：2011-01-01 00:00:00

abstract：:The recent developments in the field of recombinant DNA, protein engineering and cancer biology, have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, to regular ones. This understanding has pav...

journal_title：Current pharmaceutical design

authors： Schaedel O,Reiter Y

更新日期：2006-01-01 00:00:00

abstract：:There is a plausible role for cytokines, brain-derived neurotrophic factor (BDNF), and their interaction in major depressive disorder's (MDD) etiology. This review includes (i) briefly defining cytokines, (ii) a discussion of theories for why they may affect brain function, (iii) cross-sectional associations between c...

journal_title：Current pharmaceutical design

authors： Lotrich F

更新日期：2012-01-01 00:00:00